



European Biotechnology

Science & Industry

News

Clinical trials data
– raw or redacted?

FREE EXCERPT

CONFIDENTIAL

CENTRAL EUROPE

Novartis increases its lead in wet-AMD with take over

NORTHERN EUROPE

Finnish government tables bioeconomy investment strategy

SPECIAL

Euro Biofairs Compass – guide to life sciences events

WESTERN EUROPE

Topotarget A/S and Bioalliance Pharma form Onxeo

SOUTHERN EUROPE

Molmed's gene therapy misses endpoint in pivotal study

EASTERN EUROPE

Czech Sotio pushes immuno-oncologic cell therapy to Phase III

SCIENCE & TECHNOLOGY

New probes enable real-time imaging of cytoskeleton dynamics


4 reasons to choose Sterne Kessler

1




We prosecute when the stakes are high.

2



*We work as one team of scientifically
& technically skilled IP professionals.*

3



*We provide strategic counsel from
conception to product
launch and beyond.*

4

TOP RANKED
FIRM
U.S. NEWS

FORTUNE 500
GO-TO LAW
FIRM

GOLD
STANDARD
FOR PATENT
QUALITY

*We are recognized year after year
as a top IP firm.*

MIND + MUSCLE

in washington, dc
and at skgf.com

EDITORIAL

Efficient R&D networks based on innovation ecosystems

Roberto Gradnik, President of European Biopharmaceutical Enterprises, EBE



Roberto Gradnik, Strategic Board Advisor and former Chief Executive Officer of Stallergenes, has also been the President of the European Biopharmaceutical Enterprises (EBE) since January 2012. From 2004-2010 he served as President of the Italian biotech industry association Assobiotech. Trained as a physician, Gradnik has more than 25 years of experience in the pharmaceuticals and biotechnology sectors. Prior to his current post, he held senior positions at BASF subsidiary Knoll Group and Serono/Merck Serono.

Research and innovation models are changing dramatically. The emergence of platforms such as advanced therapeutics is accelerating a change from innovation within big centres and universities to smaller, decentralised and more focused units. Innovation is always highest where there is freedom to be creative. An EBE member company CEO whom I know put it very succinctly: “The moment my CSO knows what’s going on in the lab, we are no longer creating new innovation.” The biopharmaceutical ecosystem has grown infinitely more diverse, with a wide variety of participants contributing to nearly every aspect of development. Networks and collaborative research establishments were originally seen as a supplement to innovation, but now they have begun generating more core innovation, and are viewed as essential. Considering the fact that most European healthcare biotech companies in the fragmented European innovation landscape are SMEs (70% of the 2,000 healthcare biotech companies in Europe have less than 50 employees), we now desperately need efficient networks of innovators from science, business and public institutions to facilitate funding and enablement. There has been a paradigm shift in attitudes towards generating innovation, and this means that all stakeholders need to begin working together much more closely – all the way from the lab to the shelves of pharmacies.

The ultimate drivers in this scenario, of course, are the return on investment and the return on health. We have seen a high return on the funding and time committed to networks that have a specific focus, with the understanding that innovation now no longer necessarily comes from our own laboratories.

A critical point is that both partners in a partnership have to benefit. Networks help to

foster mutual trust, particularly where historically there has been a mutual mistrust, a situation largely born of differences in operational cultures. But the Innovative Medicines Initiative (IMI) and its successful continuation have demonstrated that these cultural gaps can also be overcome for the greater benefit of patients. Needless to say, partnerships need to demonstrate win-win, and public authorities can help encourage that. Partnerships can work to create a platform of mutual trust and benefit, just as the IMI forges programmes that foster innovation with reduced politics, creating a foundation for increased trust to flourish.

To support all of these aspects, EBE recently launched a partnership with the European Biotechnology Network (EBN) to facilitate EBE member companies’ access to diverse networks and funding opportunities across Europe. This move is aimed at helping them to build partnerships out of their comfort zone, and deliver disruptive innovation in the future. I am delighted with this collaboration, not least because it truly demonstrates the delivery power of efficient networking.

As we move forward through 2014, the two networks will bring their members together through the auspices of Horizon 2020, the IMI, and many other funding opportunities, allowing them to discover common goals around which they can combine their specialist technology platforms. From SMEs to large companies to universities – the lure of creating exciting science and business is the perfect catalyst for partnership. And as barriers between sectors and organisations fall, the results can only be positive for participants and Europe as a whole. ◀

European Biotechnology News

is published in co-operation
with the following organisations:



Europe: european-biotechnology.net



Germany: biodeutschland.org



Switzerland: swissbiotech.org



Belgium: edma-ivd.eu



Europe: eapb.org



Europe: europabio.org



Europe: cebr.net



IRISH BIOINDUSTRY ASSOCIATION

Ireland: ibec.ie/ibia



Europe: ebe-biopharma.org



Denmark: danskbiotek.dk



Norway: biotekforum.no



The Netherlands: hollandbio.nl



Austria: lifescienceaustria.at



Sweden: swedenbio.com



Finland: finbio.net



Spain: asebio.com



France: france-biotech.org



Hungary: hungarianbiotech.org



Belgium: bio.be



Portugal: www.apbio.pt



Italy: assobiotech.it

EuroBiotechNews covers the biotechnology sector of the current 28 EU member states, Norway and Switzerland. If you would like to subscribe, please refer to

www.eurobiotechnews.eu

FREE EXCERPT

CONTENTS

INSIGHT

EC tailwinds for mobile health;
GMO deadlock set to continue;
Heard in Brussels 10

EU action plan aims to reduce
medication errors 12

Adverse drug effect numbers peak;
IP Flash 14

REGULATORY AFFAIRS

Update on clinical trials 20

Breaking news from the EMA 22

ECONOMIC

Focus on newsflow and dividends 23

Stock markets 24

PERSPECTIVES

BIO 2014: Heading to the world's most
important biotech event; Finding
European partners in the EU health
competence database 15

Interview: Madiha Derouazi,
Amal Therapeutics SA 60

REGIONAL NEWS

Northern Europe 26

Central Europe 28

Western Europe 30

Eastern Europe 32

Southern Europe 34

COVER STORY



Clinical trials transparency: EMA accused of U-turn 6

For years, Europe's drug regulators pushed for the proactive publication of results from clinical trials. As the EMA prepares to present its new policy in the area, however, it has come under fire from health technology assessors and the European Ombudsman, who say the planned rules could make transparency even worse. The guidelines foresee allowing companies to redact "commercially confidential" information, while requiring researchers to sign agreements not to publish or disseminate some of the data.

SPECIAL

Euro Biofairs Compass

Europe's non-stop biotech calendar 37
Life Sciences Baltics, Vilnius 38
Biospain 2014; S. de Compostela 40
EFIB 2014, Reims 42
European Biotech Week, EU 44
CPH 2014, Paris 46
BioJapan, Yokohama 48
Bioinnovation, Gdansk 50
Bio-Europe, Frankfurt/Main 52
56th EuroPLX, Nice 54
Pharmalab, Düsseldorf-Neuss 56
Munich Biomarker Conference 58

SERVICES

Partners & Associations 4

Biopeople
News from GenSight Biologics SA,
AMSilk GmbH, Merck Millipore, Ario
Pharma Ltd, Tiziana Life Sciences plc.
and Ergomed Clinical Research Ltd 62

Company index 64

Events
What's on in Summer 2014 65

Encore 66

Imprint European Biotechnology News is published monthly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, E-Mail: service@eurobiotechnews.eu; Internet: www.eurobiotechnews.eu, Publisher: Andreas Mietzsch, Editorial Team: Thomas Gabrielczyk (Managing Editor), Derrick Williams (Co-editor), Dr. Patrick Dieckhoff, Uta Mommert, Dr. Martin Laqua, Benjamin Stolzenberg; Advertising: Oliver Schnell, +49-30-2649-2145, Christian Böhm, +49-30-2649-2149; Distribution: Marcus Laschke, +49-30-2649-2148; Printed at: Druckhaus Hamburg, Bremen; Graphic Design: Michaela Reblin. European Biotechnology Science & Industry News is only regularly available through subscription at BIOCOM AG. Annual subscription fees: €100.00, Students €50.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within 2 weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least 6 weeks before the date of expiry. Failures of delivery which BIOCOM AG is not responsible for do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Cover Photo: © fotopak/Fotolia.com. Supplements: BIO[®] Biotech Cluster Development, ASEBIO

® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

AGRIBIOTECH

Permit denied

► **Brussels** – Although more and more EU Member States are considering opting out of planting GMO acreage on their own territory, the new opportunity to ban GM crops isn't slowing down attempts to import them. At the end of May, three applications for the import of genetically engineered soybean strains did not receive the required qualified majority in the Standing Committee on the Food Chain and Animal Health (SCFCAH). The decision on whether to approve a herbicide-tolerant soybean from BASF (BPS-CV127-9) and two soybeans that lead to beneficial fatty acid profiles (Pioneer's soybean 305423 and Monsanto's Mon88705) have been now been forwarded to the Appeals Committee. If it is unable to reach the required majority, the Commission can decide to approve on its own. ◀

HEALTHCARE BUDGETS

e-Ageing

► **Brussels/Athens** – EU Health Commissioner Tonio Borg has called for more use of wireless devices in monitoring chronic diseases. Speaking in mid-May at the eHealth Forum 2014 in Athens, he said telemedicine and the current 100,000 healthcare apps on mobile phones are tools that can help promote eHealth. According to estimates from the European Commission (EC), the impact of mobile health (mHealth) on EU healthcare systems could be significant. EC Vice-President Neelie Kroes says mHealth could save €99bn annually by 2017 if its potential is fully unlocked. In April, Kroes launched the MobiGuide project, which provides personalised clinical-guideline-based guidance outside clinical environments to cardiac and diabetes patients. "mHealth has great potential to empower citizens to manage their own health and stay healthy longer, to trigger greater quality of care and comfort for patients, and to assist health professionals in their work," said Borg. ◀

Heard in Brussels

■ Europe's hungry biotech sector

Brussels – The launch of Horizon2020 and close of the first deadlines in February has shown the appetite of Europe's researchers from industry and academia for funding. A huge number of applications were received, particularly for the two-stage applications, where success rates are as low as 4% for some topics. And pass rates could remain low even at Stage 2.

A silver lining

This is scary news at first glance, but we have to look at it in multiple ways. First, these were the first deadlines after a break between FP7 and H2020, so people had been waiting awhile for the Framework carousel to start turning again. Second, the two-stage application process opens the door to a huge number of speculative attempts at Stage 1, where the application is short. In some ways it's annoying to think a half-developed idea could beat a carefully crafted effort. Indeed, exactly that has happened to enough EBN Member proposals.

Feeding the European fire

When you look at the big picture, however, you have to feel positive. Horizon 2020 is highly focussed on exploitation and raised impact. If evaluators are spoiled for choice with proposals that can deliver economic returns from biotech, then we can't complain too much. Goodness knows Europe needs to deliver money back into the system from maturing biotechnology. I'm not talking about the kind of money that comes from the acquisition of an SME for a fraction of the public money that has been poured into making it ripe for purchase, but the genuine maturation of value within Europe. These short Stage 1 proposals also enable people new to EC funding to dip a toe in the water. Much better a failed Stage 1 proposal



Claire Skentelbery,
Secretary General of the European
Biotechnology Network

that gets you thinking about working in partnership and moving your technology forward than no effort at all because a full proposal was too difficult. Failed Stage 1 proposals need to keep their chins up – after all, you've started a journey, found some new friends and there are many adventures that beckon.

From small beginnings

The big question coming up is how the new SME Instrument performs. Part of me trembles at the thought of how many applications are cooking and how many will be disappointed. The rest of me is excited – at last, something to drive SMEs forward, masters of their own destiny! We're cautiously circling the first deadlines in June, and I would imagine that the EC is also waiting with terror in its heart so see what the application process yields, and whether they'll have to get extra USB sticks out of the cupboard to store all the applications. If you feel any tremors in cyberspace on June 25, you will know the SME Instrument has delivered a bouncing big baby into the nervous arms of its midwife. ◀

News

■ Food matters

Brussels – A 70% decline in cardiovascular deaths in Denmark following a ban of trans fats has provided more strong evidence that lifestyle and diet can significantly impact health outcomes. In April, the European Commission launched the first transnational call of its novel Joint Programming Initiative 'A Healthy Diet for a Healthy Life' (JPI HDHL). This funding round will focus on the validation of biomarkers that indicate nutritional effects in the development of foods. Selected projects will be announced in October. Kick-off is in December.

■ EU synergies

London – The European Chemicals Agency (ECHA) and European Medicines Agency (EMA) are joining forces in predictive toxicology, measuring the environmental impact of pharmaceuticals, and defining maximum residue limits for pharmacologically active substances. In mid-May, EMA chief Guido Rasi and ECHA-head Geert Dancet signed a memorandum of understanding on the partnership.

■ Taking the EC to court

Stockholm/Brussels – Sweden is suing the European Commission for its delay in defining scientific criteria needed to identify and ban hormone-like substances in products that affect human health and the environment. According to Environment minister Lena Ek, the Commission missed a December 2013 deadline to provide testing criteria. To speed up the process, her government will now take the case to the European Court of Justice.

MEDICATION ERRORS

European agencies take action to address a widely perceived danger

► **London/Brussels** – In the US, medication errors are estimated to cause a stunning 400,000 deaths a year, making them the third leading cause of death there. European data suggest that medical errors and healthcare-related adverse drug reactions (ADRs) occur in 8% to 12% of all hospitalisations, and cause about 850,000 adverse events a year. While accurate figures are hard to determine, four out of five EU citizens on average perceive medication errors as a prominent problem in their country, according to a 2006 Eurobarometer survey. What's more, medication errors are "the single most common preventable cause of adverse events in medication practice," according to the European Medicines Agency (EMA). Together with EU national competent authorities, the EMA agreed an action plan to address the problem in late April.

Based on discussions with over 200 stakeholders in the field, the agencies' strategy focuses on improving reporting of ADRs as a prerequisite for risk minimisation and prevention strategies. The action plan includes recommendations that are to be implemented by autumn of 2015, among them:

- the implementation of a good practices guide, including common rules for coding and reporting medication errors as well as data-sharing,
- the establishment of a good practice guide on risk minimisation and prevention of medication errors, including specific patient subgroups such as children and geriatric patients.
- the development of an EMA concept paper on the best use of the Medical Dictionary for Regulatory Activities (MedDRA) terminology to address medication-error specific coding, data retrieval and analysis issues.
- raising awareness and implementing a communication strategy as part of the European Commission's Joint Action 'Strengthening Collaboration for Operating Pharmacovigilance in Europe' (SCOPE)

The EMA and the national Agencies also want to improve contact between themselves as well as with patient/consumer groups as well as healthcare professionals to assess and systematically prevent risks associated with medication errors throughout a pharmaceutical product's entire lifecycle. ▼

Table 1: Incidence of medication errors in Europe

Stage in the medication use system	Ambulatory care	Hospital	Comments
► Prescribing	7.5%	0.3-9.1%	% of medication orders
► Dispensing	0.08%	1.6-2.1%	% of medication orders
► Administration	Not available	49.3% 5.1-47.5% 2.4-8.6% 7.2-9.1% 10.5% 2.4-9.7%	Direct observation studies: – IV medicines dose prepared on wards – Traditional floor stock or ward stock systems – Ward stock system with original prescription and daily ward visits by pharmacists – Patient prescription distribution systems – Unit dose drug distribution manual system – Unit dose drug distribution, computerised or automated system


COMPANY AND ADVERTISER INDEX

FREE EXCERPT

PROMOCCELL

A wide range of cell-based assays

► Heidelberg – PromoKine offers a wide range of products for cell analysis, including numerous kits for fast, convenient and sensitive measurement of cell viability/proliferation, cytotoxicity, cell death and apoptosis, cell stress and metabolism, as well as reporter gene expression. PromoKine's Fluorometric Cell Viability Kits are based on resazurin or calcein-AM conversion, while the Colorimetric Cell Viability Kits utilise reduction of different tetrazolium salts. The Bioluminescent Cell Viability Kits measure ATP levels as a marker for cell viability in a luciferase assay, and the Cell Proliferation



Kit determines the number of cell divisions using flow cytometry.

The cytotoxicity kits quantify the amount of lactate dehydrogenase (LDH) or adenylate kinase (AK) released from damaged cells, either colorimetrically or by using a luminometer. PromoKine's apoptosis assays include various kits for detection and quantification of caspase activity, annexin V binding, DNA fragmentation or mitochondrial changes. Moreover, PromoKine provides reporter assay kits (β-galactosidase, luciferase, GFP) as well as a selection of small-sized reporter plasmids and fusion plasmids (target gene fused with GFP or luciferase gene). ▼

Contact

Promocell GmbH

Phone: +49 6221 - 649 34 0

info@promokine.info, www.promokine.info

AB-Biotics (E).....	34	Horizon Discovery Ltd. (UK).....	31
Abbott GmbH & Co KG (GER).....	20	Hospira One 2 One Global Pharma (USA).....	CP4
Ablynx NV (B).....	20	ICS Convention Design Inc. (I).....	48, 49
AC Immune SA (CH).....	28	Immunocore Ltd. (UK).....	62
ADC Therapeutics (CH).....	20	Kymab Ltd. (UK).....	31
Amakem NV (B).....	21	Life Science Austria LISA (A).....	36
Amal Therapeutics S.A. (CH).....	60, 61	Lundbeck A/S (DK).....	26
Amega Biotech (AR).....	46	Lysogene SAS (F).....	31
Amgen Inc. (USA).....	29, 62	Mabion S.A. (PL).....	46
AMSilk GmbH (GER).....	62	Medimmune Ltd (UK).....	20
Andelam B.V. (NL).....	32	Merck KGaA (GER).....	38
Arcticzymes AS (N).....	26	Merck Millipore (GER).....	62
arGEN-X B.V. (NL).....	29	Merck Serono (CH).....	3
Ario Pharma Ltd. (UK).....	62	Mitsubishi Tanabe Pharma (JP).....	21
ASEBIO – BIOSPAIN 2014 (E).....	40, 41, Supplement	MLM Medical Labs GmbH (GER).....	9
AstraZeneca AB (S/UK).....	20, 30	MolMed S.p.A. (I).....	34
Barentzymes AS (N).....	26	Monsanto (USA).....	10
BASF SE (GER).....	3, 10	Mucosis BV (NL).....	31
Bayer Healthcare AG (GER).....	28	NATAC (E).....	34
Bayer Pharma AG (GER).....	29	NatureWorks LLC (USA).....	42
Bio-Tech Consulting (PL).....	33	Newron Pharmaceuticals S.p.A. (I).....	34, 62
Bioalliance Pharma SA (F).....	30	Nicox S.A. (F).....	34
BIOCOM AG (GER).....	13, 60, 61	nova-Institut (GER) – 3 rd Conference on CO ...	59
Biogen Idec (USA).....	20, 22, 27	Novartis AG (CH).....	29, 62
Bioiberica S.A. (E).....	34	NovImmune S.A. (CH).....	23
BioM GmbH (GER).....	58, Supplement	Novo Nordisk A/S (DK).....	29
Biomedal S.L. (E).....	34	Novo Seed (DK).....	31
BIOPOLIS S.L. (E).....	34	Ophtotech Inc. (CH).....	29
biosaxony e.V. (GER) – Bionection 2014.....	27	Orphan Biovitrum (S).....	20
Biosearch Technologies (E).....	34	Oxford Immunotec (UK).....	23
Biosidus (AR).....	46	Parexel (USA).....	38
BioTOP Berlin-Brandenburg (GER).....	CP3	Pevesa Biotech SA (E).....	34
Biovex (USA).....	62	Pfizer Inc. (USA).....	30
Bloomberg (USA).....	23	Pierre Fabre Oncology Laboratories (F).....	62
BOEHMERT & BOEHMERT (GER).....	17	Pioneer Hi-Bred International Inc. (USA).....	10
Boehringer Ingelheim (GER).....	20, 21, 60	Piramal Imaging SA (CH).....	28
Burrill & Company (USA).....	33	PowderMed Ltd (UK).....	62
Calico GmbH (GER).....	28	PPF Group (HUN).....	32
Changchun BCBT Biotechnology Co. (VRC).....	31	Pro Science Polska – Bioinnovation 2014 (PL).....	50, 51
Chelsea Therapeutics (USA).....	26	Pro-Science Poland Ltd.	50
Cobra Biologics (UK).....	21	Promocell GmbH (GER).....	64
Coca-Cola (USA).....	42	Proviro GmbH (GER).....	28
CombinatoRx (UK).....	31	Qiagen NV (GER).....	29
Complix N.V. (B).....	62	RauCon (GER) – EuroPLX.....	54, 55
Concept Heidelberg (GER) – PharmaLab 2014.....	56, 57	Rentschler Biotechnologie GmbH (GER).....	19
Cosmo Pharmaceuticals (I).....	62	Roche AG (CH).....	21
Covagen AG (CH).....	21	Salans FMC SNR Denton Europe LLP (GER/USA).....	11
Dainippon Sumitomo Pharma Co. Ltd. (JP).....	26	Selvita S.A. (PL).....	33
Dako A/S (DK).....	26	SeproxBiotech (E).....	34
DSM (NL).....	42	Shire plc (IRL).....	29, 62
e-Therapeutics plc (UK).....	20	Smithers (UK) – EFIB Conference 2014.....	42, 43
EBD Group (GER) – BIO-Europe 2014.....	52, 53	Sobi AB (S).....	27
Eli Lilly (USA).....	20, 21, 29	Sofinnova (F).....	31
Enterprise Lithuania (LT).....	38	Sotio a.s. (CR).....	32
Ergomed Group (UK).....	62	STALLERGENES SA (F).....	3
Eupharmed (I).....	34	Sterne, Kessler, Goldstein & Fox (USA).....	CP2, 14
EuropaBio (B) – European Biotech Week.....	44, 45	Südzucker AG (GER).....	42
European Biotechnology Network (B).....	16	SV Life Sciences (UK).....	29
ExonHit (F).....	62	Swiss Healthcare Investments Ltd.	29
Fördergesellschaft IZB (GER).....	7	Teva Pharmaceutical Industries Ltd. (IL).....	33, 38
Fournier-Solvay Pharma (F).....	62	TherapeuticProteins International.....	46
Fovea-Sanofi (F).....	62	Tiziana Life Sciences plc (UK).....	62
Galderma SA (F).....	62	Topo Target A/S (DK).....	30
Gedeon Richter Ltd. (HUN).....	32	Toscana Promozione (I).....	15
Genmab A/S (DK).....	21	Toxicon Corp. (USA).....	46
GenSight Biologics (F).....	62	Trophos SA (F).....	20
Genzyme (USA).....	38	TxCell S.A. (F).....	31
GlaxoSmithKline (UK).....	21, 38	UBMi B.V. (NL) – CPhi worldwide.....	46, 47
Glycotope GmbH (GER).....	23	Unilever (CH).....	42
GW Pharmaceuticals (UK).....	23	uniQure BV (NL).....	23
Hessen Trade & Invest GmbH (GER).....	52	ZAMBON Company S.p.A. (I).....	34
High-Tech Gründerfonds Management (GER).....	23, 60		



**Life Sciences.
Living Research.
Berlin. Brandenburg.**



A vibrant network.

Berlin-Brandenburg is one of Europe's leading locations for the Life Sciences. It is also an R&D capital that magnetically attracts the world's top scientists. Here you'll find attractive funding conditions, close linkages between business and science, the highest concentration of R&D in Europe, a dynamic startup scene and a multifaceted entrepreneurial environment made up of more than 500 pharmaceutical, biotech and medical technology companies. Come discover this one-of-a-kind landscape for scientists and entrepreneurs.

www.businesslocationcenter.de/healthcareindustries

Visit us at BIO International Convention 2014!

June 23-26, San Diego, California | German Pavilion | Booth 4513-01

THE GERMAN CAPITAL REGION
excellence in life sciences & healthcare

THE POWER OF COMPLEMENTARY CAPABILITIES

GLOBAL REACH | SECURITY OF SUPPLY | EFFICIENCY



Let's talk

KNOWLEDGE | EXPERIENCE | EXPERTISE

Call +1-224-212-2267 or +44 (0) 1926 835 554
or e-mail one2one@hospira.com



PARENTERAL CONTRACT MANUFACTURING
SERVICE OF HOSPIRA



Hospira, Inc., 275 North Field Drive, Lake Forest, IL 60045
P14-0265-1-8.25x10.875-Apr., 14

PLEASE VISIT US AT

IATI Biomed 2014, Tel Aviv | ICSE/CPhI 2014, Paris